Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review

Area of Science:

• Oncology
• Ophthalmology
• Pharmacology

Background:

• Chemotherapy can cause ocular adverse events (OAEs), but they are rarely severe.
• Molecularly targeted agents (MTAs) represent a newer class of cancer drugs.
• The ocular toxicity profile of MTAs may differ significantly from traditional chemotherapy.

Purpose of the Study:

• To review ocular adverse events (OAEs) associated with molecularly targeted agents (MTAs) approved for solid tumors.
• To increase awareness among oncologists regarding potential severe OAEs with MTAs.
• To emphasize the importance of ophthalmic assessment for patients experiencing specific symptoms.

Main Methods:

• Systematic literature review of OAEs reported with MTAs in solid tumors.
• Analysis of the frequency and severity of OAEs across different MTAs.
• Identification of key symptoms indicative of potentially severe OAEs.

Main Results:

• Many MTAs are associated with frequent and potentially severe OAEs.
• Ocular toxicities with MTAs can be dose-limiting.
• Severe pain and visual impairment are critical symptoms requiring immediate ophthalmic evaluation.

Conclusions:

• Oncologists must be aware of the spectrum of OAEs linked to MTAs.
• Early referral to ophthalmology is essential for timely diagnosis and management of severe OAEs.
• Awareness of MTA-induced OAEs improves patient care in clinical practice and trials.